Navigation Links
International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis

WORCESTER, Massachusetts, July 08, 2007 /PRNewswire/ --

- ENDORSE Global Findings Highlight the Need to Urgently Implement Hospital-Wide Strategies to Optimize VTE Management: Systematically Assess Patient Risk for VTE and Provide Appropriate prophylaxis to Prevent VTE

Venous thromboembolism (VTE) risk is high among hospital patients and most of these at-risk patients are not protected with adequate prophylaxis according to data from the international ENDORSE (Epidemiologic International Day for the Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Setting) study presented today at the XXIst International Society on Thrombosis and Haemostasis (ISTH) congress in Geneva.

VTE is a preventable disease which contributes significantly to morbidity and mortality among patients hospitalized for acute medical and surgical illnesses. Many complications and deaths due to VTE could be prevented using thromboprophylaxis as recommended by evidence based guidelines, but some studies have shown that there is a gap between evidence and practice in the hospital setting. Lack of awareness and uncertainty about the prevalence of patients at risk for VTE are among the major reasons accounting for this gap (1, 2). To date, there has been no large international study performed in hospitals selected at random around the world to evaluate VTE risk and prophylaxis practice globally.

ENDORSE collected data on more than 60,000 patients who were surveyed across 358 acute care hospitals randomly selected in 32 countries, encompassing 5 continents. All participating hospitals followed the same standard multinational protocol to survey the patients present in the wards.

The main objectives of ENDORSE were to assess the prevalence of VTE risk in the acute hospital care setting and to determine the proportion of at-risk patients who receive recommended prophylaxis using the d efinition of patients at risk of VTE and prophylaxis recommendations provided by the of Chest Physicians (ACCP) evidence-based consensus guidelines (3). The study included two categories of hospitalized patients: patients in medical wards 40 years of age or older, and patients in surgical wards, 18 years or older.

Doctor Fred Anderson, Director of the Center for Outcomes Research at the University of Massachusetts Medical School who conducted the study commented "ENDORSE is the first study to provide a global view of VTE risk and prophylaxis practices throughout the world. With more than 60,000 patients studied in more than 30 countries, the scope of ENDORSE is unprecedented. In view of the quality of the data collected and a common method to assess patients at risk for VTE and prophylaxis used, this study gives us a unique picture both globally and locally about the extent of the hospitalized patient population at risk for VTE and how these patients are managed."

ENDORSE demonstrates the high prevalence of patients at risk for VTE: 52% of hospitalized patients surveyed were at risk for VTE, corresponding to 64% of surgical patients and 42% of medical patients. The prevalence of patients at risk was consistent across the countries surveyed, demonstrating the importance of VTE risk on a global scale.

Importantly, when considering the use of recommended prophylaxis in hospitals, only 50% of hospitalized patients at risk for VTE received a method of prophylaxis recommended by the ACCP, corresponding to 59% of surgical and 40% of medical patients at risk for VTE. The use of recommended prophylaxis varied across countries; however, it was globally sub-optimal and even more so in medical than surgical patients, as the majority of medical patients at risk for VTE (60%) did not receive recommended prophylaxis.

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety i ssue in hospitalized patients, as the majority of them are at risk for VTE. This is really a global concern as a high proportion of patients at risk for VTE is observed across all the countries surveyed. Importantly, ENDORSE showed that one out of 2 hospitalized patients at risk for VTE were not receiving any recommended form of prophylaxis. It definitely shows that there is globally a sub-optimal use of VTE prophylaxis and this is even more pronounced among medically ill patients."

Commenting on the study, Doctor Ander Cohen, Co-chair of the ENDORSE Steering Committee, said "ENDORSE findings provide strong evidence of the need to increase awareness about the high prevalence of VTE risk among hospitalised medical and surgical patients. Importantly, it highlights the need to significantly improve the use of appropriate prophylaxis in patients at risk for VTE. In the United States for instance, VTE prophylaxis has been identified as the number #1 strategy to improve patient safety in the hospital. If we want to improve hospital patient outcomes, we urgently need to implement hospital-wide strategies to identify all surgical and medical patients at risk for VTE and provide appropriate prophylaxis to prevent VTE."

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE).

VTE is a common complication among patients hospitalized for major surgery or with a severe medical illness such as cancer or cardiopulmonary disease, particularly when accompanied by prolonged bed rest, age over 60, or a previous history of VTE.

About COR (Center for Outcomes Research)

The Center for Outcomes Research (COR) serves as the scientific coordinating center for a growing number of national and international outcomes registries. COR's responsibilities include maintaining patient and physician confidentiality, design of data collection instruments, data management and publication development.

Established in 1994, COR is an outgrowth of the Worcester Deep Vein Thrombosis Study, a five-year NIH-supported program, which demonstrated that physicians are more likely to improve patient management practices if they are provided with valid data on their own practices and outcomes along with regional and national benchmarks.

About the University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than US$174 million in research funding annually, 80 percent of which comes from federal funding sources. For more information, visit www.umassmed.edu.

ENDORSE study funding

The Center for Outcomes Research (COR) at the University of Massachusetts Medical School received an unrestricted grant from sanofi-aventis to support this work.

References

1. Goldhaber SZ, Tapson VF. Am J Cardiol. 2004;93:259-62.

2. Anderson FA Jr, et al. Blood. 2003;102 [abstract 1146].

3. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the seventh ACCP conference on Antithrombotic and Thrombotic Therapy. Chest. 2004;126:338S-400S.

CONTACT: Media Contact: Alison M. Duffy, Public Affairs and Publications,+1-508-856-2000, alison.duffy@umassmed.edu

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
6. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
Breaking Medicine News(10 mins):